TY - JOUR AU - Chan, I. S. AU - Bhatia, S. AU - Kaufman, H. L. AU - Lipson, E. J. PY - 2018 DA - 2018// TI - Immunotherapy for merkel cell carcinoma: a turning point in patient care JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0335-9 DO - 10.1186/s40425-018-0335-9 ID - Chan2018 ER - TY - JOUR AU - Nghiem, P. T. AU - Bhatia, S. AU - Lipson, E. J. AU - Kudchadkar, R. R. AU - Miller, N. J. AU - Annamalai, L. PY - 2016 DA - 2016// TI - PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1603702 DO - 10.1056/NEJMoa1603702 ID - Nghiem2016 ER - TY - JOUR AU - D'Angelo, S. P. AU - Russell, J. AU - Lebbe, C. AU - Chmielowski, B. AU - Gambichler, T. AU - Grob, J. J. PY - 2018 DA - 2018// TI - Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.0077 DO - 10.1001/jamaoncol.2018.0077 ID - D'Angelo2018 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. S. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - D'Angelo, S. P. PY - 2018 DA - 2018// TI - Updated efficacy of avelumab in patients with previously treated metastatic merkel cell carcinoma after >/=1 year of follow-up: JAVELIN merkel 200, a phase 2 clinical trial JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-017-0310-x DO - 10.1186/s40425-017-0310-x ID - Kaufman2018 ER - TY - JOUR AU - Topalian, S. L. AU - Bhatia, S. AU - Kudchadkar, R. R. AU - Amin, A. AU - Sharfman, W. H. AU - Lebbe, C. PY - 2018 DA - 2018// TI - Nivolumab (nivo) as neoadjuvant therapy in patients with resectable merkel cell carcinoma (MCC) in CheckMate 358 JO - JCO VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.9505 DO - 10.1200/JCO.2018.36.15_suppl.9505 ID - Topalian2018 ER - TY - JOUR AU - Nghiem, P. AU - Bhatia, S. AU - Lipson, E. J. AU - Sharfman, W. H. AU - Kudchadkar, R. R. AU - Brohl, A. S. PY - 2019 DA - 2019// TI - Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.18.01896 DO - 10.1200/JCO.18.01896 ID - Nghiem2019 ER - TY - JOUR AU - Bichakjian, C. K. AU - Olencki, T. AU - Aasi, S. Z. AU - Alam, M. AU - Andersen, J. S. AU - Blitzblau, R. PY - 2018 DA - 2018// TI - Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology JO - J Natl Compr Cancer Netw VL - 16 UR - https://doi.org/10.6004/jnccn.2018.0055 DO - 10.6004/jnccn.2018.0055 ID - Bichakjian2018 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. AU - Weber, J. S. AU - Hamid, O. AU - Lebbe, C. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - JOUR AU - Paulson, K. G. AU - Voillet, V. AU - McAfee, M. S. AU - Hunter, D. S. AU - Wagener, F. D. AU - Perdicchio, M. PY - 2018 DA - 2018// TI - Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-06300-3 DO - 10.1038/s41467-018-06300-3 ID - Paulson2018 ER - TY - JOUR AU - Paulson, K. G. AU - Park, S. Y. AU - Vandeven, N. A. AU - Lachance, K. AU - Thomas, H. AU - Chapuis, A. G. PY - 2018 DA - 2018// TI - Merkel cell carcinoma: current US incidence and projected increases based on changing demographics JO - J Am Acad Dermatol VL - 78 UR - https://doi.org/10.1016/j.jaad.2017.10.028 DO - 10.1016/j.jaad.2017.10.028 ID - Paulson2018 ER - TY - JOUR AU - Heath, M. AU - Jaimes, N. AU - Lemos, B. AU - Mostaghimi, A. AU - Wang, L. C. AU - Penas, P. F. PY - 2008 DA - 2008// TI - Clinical characteristics of merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features JO - J Am Acad Dermatol VL - 58 UR - https://doi.org/10.1016/j.jaad.2007.11.020 DO - 10.1016/j.jaad.2007.11.020 ID - Heath2008 ER - TY - JOUR AU - Feng, H. AU - Shuda, M. AU - Chang, Y. AU - Moore, P. S. PY - 2008 DA - 2008// TI - Clonal integration of a polyomavirus in human merkel cell carcinoma JO - Science VL - 319 UR - https://doi.org/10.1126/science.1152586 DO - 10.1126/science.1152586 ID - Feng2008 ER - TY - JOUR AU - Wong, S. Q. AU - Waldeck, K. AU - Vergara, I. A. AU - Schroder, J. AU - Madore, J. AU - Wilmott, J. S. PY - 2015 DA - 2015// TI - UV-associated mutations underlie the etiology of MCV-negative merkel cell carcinomas JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-1877 DO - 10.1158/0008-5472.CAN-15-1877 ID - Wong2015 ER - TY - JOUR AU - Schadendorf, D. AU - Lebbe, C. AU - Zur Hausen, A. AU - Avril, M. F. AU - Hariharan, S. AU - Bharmal, M. PY - 2017 DA - 2017// TI - Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs JO - Eur J Cancer VL - 71 UR - https://doi.org/10.1016/j.ejca.2016.10.022 DO - 10.1016/j.ejca.2016.10.022 ID - Schadendorf2017 ER - TY - JOUR AU - Lipson, E. J. AU - Vincent, J. G. AU - Loyo, M. AU - Kagohara, L. T. AU - Luber, B. S. AU - Wang, H. PY - 2013 DA - 2013// TI - PD-L1 expression in the merkel cell carcinoma microenvironment: association with inflammation, merkel cell polyomavirus and overall survival JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0034 DO - 10.1158/2326-6066.CIR-13-0034 ID - Lipson2013 ER - TY - JOUR AU - Zimmer, L. AU - Apuri, S. AU - Eroglu, Z. AU - Kottschade, L. A. AU - Forschner, A. AU - Gutzmer, R. PY - 2017 DA - 2017// TI - Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma JO - Eur J Cancer VL - 75 UR - https://doi.org/10.1016/j.ejca.2017.01.009 DO - 10.1016/j.ejca.2017.01.009 ID - Zimmer2017 ER - TY - JOUR AU - Winkler, J. K. AU - Schneiderbauer, R. AU - Bender, C. AU - Sedlaczek, O. AU - Fröhling, S. AU - Penzel, R. AU - Enk, A. AU - Hassel, J. C. PY - 2016 DA - 2016// TI - Anti-programmed cell death-1 therapy in nonmelanoma skin cancer JO - British Journal of Dermatology VL - 176 UR - https://doi.org/10.1111/bjd.14664 DO - 10.1111/bjd.14664 ID - Winkler2016 ER - TY - JOUR AU - Butte, M. J. AU - Keir, M. E. AU - Phamduy, T. B. AU - Sharpe, A. H. AU - Freeman, G. J. PY - 2007 DA - 2007// TI - Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses JO - Immunity VL - 27 UR - https://doi.org/10.1016/j.immuni.2007.05.016 DO - 10.1016/j.immuni.2007.05.016 ID - Butte2007 ER - TY - JOUR AU - Wang, C. AU - Thudium, K. B. AU - Han, M. AU - Wang, X. T. AU - Huang, H. AU - Feingersh, D. PY - 2014 DA - 2014// TI - In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0040 DO - 10.1158/2326-6066.CIR-14-0040 ID - Wang2014 ER - TY - JOUR AU - Boyerinas, B. AU - Jochems, C. AU - Fantini, M. AU - Heery, C. R. AU - Gulley, J. L. AU - Tsang, K. Y. PY - 2015 DA - 2015// TI - Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0059 DO - 10.1158/2326-6066.CIR-15-0059 ID - Boyerinas2015 ER - TY - JOUR AU - Fujii, R. AU - Friedman, E. R. AU - Richards, J. AU - Tsang, K. Y. AU - Heery, C. R. AU - Schlom, J. PY - 2016 DA - 2016// TI - Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab JO - Oncotarget VL - 7 ID - Fujii2016 ER - TY - JOUR AU - Khanna, S. AU - Thomas, A. AU - Abate-Daga, D. AU - Zhang, J. AU - Morrow, B. AU - Steinberg, S. M. PY - 2016 DA - 2016// TI - Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.07.033 DO - 10.1016/j.jtho.2016.07.033 ID - Khanna2016 ER - TY - JOUR AU - Postow, M. A. AU - Callahan, M. K. AU - Barker, C. A. AU - Yamada, Y. AU - Yuan, J. AU - Kitano, S. PY - 2012 DA - 2012// TI - Immunologic correlates of the abscopal effect in a patient with melanoma JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1112824 DO - 10.1056/NEJMoa1112824 ID - Postow2012 ER -